Skip to main content
. 2021 May 24;2(7):100194. doi: 10.1016/j.jtocrr.2021.100194

Table 2.

Comparison With Retrospective Studies

Parameter GoYLC2020 Galvez-Nino et al.25 Chen et al.21 Liu et al.20 Pan et al.24 Tanaka et al.23 Sacher et al.4 Wang et al.22
Patient age evaluated <40 <40 <35 <35 <40 <40a <40a <30
Tumor type
 N 133 166 89 82 270 81 81 41
 Adenocarcinoma, n (%) 115 (86.5) 105 (63.3) 89 (100) 37 (45.1) 194 (71.8) 81 (100) 68 (84.0) 32 (78.0)
 SCLC, n (%) 6 (4.5) 21 (25.9) 18 (6.7) 2 (4.9)
 Squamous cell, n (%) 9 (6.8) 13 (7.8) 9 (11.0) 42 (15.6) 3 (3.7) 1 (2.4)
Stage
 N 130 137b 89 63 252 81 81 39b
 I-III, n (%) 27 (20.8) 10 (7.3) 74 (83.1) 32 (50.8) 84 (33.3) 23 (28.4) 28 (34.6) 19 (48.7)
 IV, n (%) 103 (79.2) 116 (84.7) 15 (16.9) 31 (49.2) 159 (63.1) 58 (71.6) 53 (65.4) 20 (51.2)
 Unknown/other, n (%) 11 (8.1) 9 (3.6)
Mutations
 N 128 0 89 18 c,d 81 d 22c
 EGFR, n (%) 36 (28.1) 19 (21.4) 10 (55.6) 29 (39.7)e 24 (29.6) 25 (32.1)f 5 (22.7)
 ALK, n (%) 42 (32.8) 15 (16.9) 5 (27.8) 25 (33.8)g 33 (40.7) 13 (19.1)h 6 (27.2)
 Mutation negative, n (%) 13 (10.2) 29 (32.6) 3 (16.7) 22 (27.1) 7 (31.8)
Smoking, n (%)
 N 121 137b 89 81 252 81 81 41
 Smoking, n (%) 33 (27.2) 17 (14.4) 9 (10.1) 23 (28.4) 48 (19.0) 36 (44.4) 27 (33.3) 5 (12.2)
 Nonsmoking, n (%) 88 (72.8) 101 (73.7) 80 (89.9) 58 (71.6) 196 (77.8) 45 (55.6) 54 (66.7) 36 (87.8)
 Unknown/not registered, n (%) 19 (13.9) 8 (3.2)
a

Patients less than 40 were a subgroup within the study.

b

Patients with NSCLC only.

c

Patients with adenocarcinoma only.

d

Number of patients with data available for EGFR and ALK mutations differed between groups.

e

n = 73.

f

n = 78.

g

n = 74.

h

n = 68.